Two Sigma Advisers LP boosted its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 823.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 739,522 shares of the medical equipment provider’s stock after buying an additional 659,412 shares during the quarter. Two Sigma Advisers LP owned approximately 0.37% of Zimmer Biomet worth $89,238,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Bank of Nova Scotia Trust Co. bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $112,000. FNY Managed Accounts LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $117,000. Cerebellum GP LLC bought a new position in Zimmer Biomet in the 4th quarter valued at approximately $133,000. Steward Partners Investment Advisory LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at approximately $140,000. Finally, Chesley Taft & Associates LLC bought a new position in Zimmer Biomet in the 4th quarter valued at approximately $202,000. Institutional investors and hedge funds own 86.64% of the company’s stock.
ZBH has been the subject of a number of research reports. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a report on Tuesday, November 14th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, November 20th. Canaccord Genuity reiterated a “hold” rating and issued a $125.00 price objective on shares of Zimmer Biomet in a report on Tuesday, December 19th. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price objective for the company in a report on Tuesday, December 19th. Finally, Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet presently has an average rating of “Buy” and a consensus price target of $141.06.
Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $117.92 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The stock has a market cap of $24,024.15, a P/E ratio of 14.73, a price-to-earnings-growth ratio of 2.06 and a beta of 1.13.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the consensus estimate of $2.10. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.14 EPS. sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.81%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 10.65%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.